SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak current-quarter outlook, attributed to softer PC demand and manufacturing constraints, overshadowed its quarterly results and triggered a historic selloff, with analyst downgrades adding pressure. Traders are split between viewing the decline as an overreaction and buying opportunity and expecting more downside as they question the companys turnaround.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks sharp selloff despite a strong earnings beat, higher guidance and an announced stock split is driving discussion, with traders pointing to the broader tech and memory-sector pullback and worries that memory pricing and earnings growth may be nearing a cyclical peak. Many see the decline as an overreaction and are buying the dip, while others argue the stock is being repriced for slowing growth and future memory-cycle risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits sharp selloff follows a strong quarterly report that was overshadowed by weaker-than-expected user metrics and revenue guidance, declining Google search referrals, and plans to test a logged-in-only experience. Traders debate whether the reaction is excessive given revenue growth and profitability or whether traffic and login barriers threaten future user growth and ad revenue.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, amplified by Intels weak outlook and concerns about tech earnings and AI spending, has hit SOXL; traders are split between buying an oversold dip and expecting further downside, with the funds 3x leverage magnifying the volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader AI and tech sell-off following Amazon and Intel results, as investors question whether heavy data-center spending will generate adequate returns. Traders are also debating reports that Nvidia may guarantee financing for an Nscale facility serving Anthropic: bears see added circular-financing risk, while bulls view ongoing infrastructure spending as support for chip demand and treat the drop as a buying opportunity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a tech-led selloff, as traders focus on weak outlooks from major companies and concerns that heavy AI infrastructure spending may not pay off quickly enough. The conversation is broadly bearish, though some traders view the pullback as a buying opportunity and expect a bounce.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broader tech and semiconductor selloff, with traders linking the pressure to Intels weak outlook and renewed concerns about AI spending and stretched valuations. The community is divided over whether Intels struggles could benefit AMD through market-share gains or whether sector-wide risk-off sentiment will dominate ahead of AMDs earnings.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Shares are under pressure as traders react to DaVitas preliminary outlook that DefenCaths post-TDAPA reimbursement contribution could fall significantly after the first quarter of 2027, raising concerns about the drugs revenue and adoption outlook. The community is divided: some see DaVitas comments as limited modeling rather than a company-wide forecast and point to CMSs finalized add-on rate, while others want management to clarify the impact and criticize its focus on acquisitions over buybacks.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A broad equity selloff, amplified by tech weakness after Amazons AI-spending outlook and Intels forecast disappointed investors, is driving SPY discussion. Traders debate whether this signals a deeper unwind of the AI trade or a pullback to buy, while some also point to oil and geopolitical risks and midterm uncertainty.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp semiconductor-sector selloff, with traders pointing to Intels weak forward outlook and PC-demand concerns alongside broader tech earnings pressure and worries about AI valuations and spending. The community is split between calling the drop a buying opportunity on persistent AI-chip demand and warning that the correction could deepen.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CYDY Stock Falls Despite Positive Cancer Study Data – Retail Says CytoDyn Is ‘Here To Stay’

Equity

CytoDyn presented new data from a Phase 2 study for metastatic colorectal cancer at the AACR Annual Meeting in San Diego.

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development and potential commercialization of its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its current clinical development activities focus on solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer, and the development of a long-acting version of leronlimab. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Cytodyn Inc

Bullish Sentiment

<ul><li>&nbsp;The study evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth.</li><li>The study showed positive results for Leronlimab in combination with other therapies, supporting CCR5 as a promising treatment target.</li><li>In a subset of patients, tumor DNA levels dropped by about 70% within two weeks.</li></ul>CytoDyn Inc. (CYDY) shares were in the spotlight on Wednesday after the biotech firm reported encouraging early data from an ongoing study of its treatment for metastatic colorectal cancer.At the time of writing, <a href="https://stocktwits.com/symbol/CYDY">CYDY shares</a> were trading 5% lower.<h2>Leronlimab Shows Promise Against Tumor Growth</h2>The study, presented at the AACR Annual Meeting, evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth. Early findings showed promising clinical and biomarker activity, particularly in heavily pretreated patients.CCR5 protein was found in all 33 patients in the study, suggesting it is common in metastatic colorectal cancer and could be a good target for new treatments. The study showed that blocking CCR5 with Leronlimab may help change the environment around the tumor and boost the immune response.In a subset of patients, tumor DNA levels dropped by about 70% within two weeks, indicating a rapid response to treatment. The combination therapy also showed a favorable safety profile, with no major dose-limiting side effects. The trial is ongoing and continues to enroll patients, CytoDyn added.“The early biomarker and clinical signals observed in our ongoing Phase 2 mCRC study reinforce the potential of leronlimab-based combination approaches to enhance immune engagement and address resistance in heavily pretreated patients,” said CEO Jacob P. Lalezari.<h2>How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.One bullish user said, “CYDY and Leronlimab are here to stay in the fight against cancer.”<stembedurl>https://stocktwits.com/Buyout_offer/message/650997895</stembedurl>Another user hoped for a positive response from the FDA.<stembedurl>https://stocktwits.com/PhyscoChicken/message/650962093</stembedurl>The stock has gained more than 14% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hands using a mobile phone to analyze financial data with a laptop in the background, displaying graphs and charts for business planning. NOK, INTC and MRVL stocks hit fresh records. (Picture source: Getty)

CytoDyn Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.224
Prev Close	$0.225
Open	$0.2201
Dividend Yield	0.00%
50-Day Moving Average	$0.2146
Beta	0.45
Avg. Volume	1.69M
PE Ratio	-5.08

52-Week High	$0.397
52-Week Low	$0.1829
Market Capitalization	$330.64M
EPS (Annual)	-$0.0343
Price to Book	-3.34
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CYDY Fundamentals